Literature DB >> 15141336

In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia.

J Chandenier1, K D Adou-Bryn, C Douchet, B Sar, M Kombila, D Swinne, M Thérizol-Ferly, Y Buisson, D Richard-Lenoble.   

Abstract

In order to determine the potential role that various antifungal agents might have in the management of cryptococcosis in tropical areas, the in vitro susceptibility of Cryptococcus neoformans isolates from Africa ( n=52) and Cambodia ( n=110) to three antifungal agents (amphotericin B, fluconazole and voriconazole) were compared using the E-test method. The results of this study (i) confirm the value of the E-test for testing the in vitro susceptibility of C. neoformans towards voriconazole; (ii) provide the first evidence demonstrating good activity of amphotericin B, fluconazole and voriconazole against Cambodian isolates; and (iii) show there are differences in susceptibility between African and Asian C. neoformans isolates, with Cambodian isolates appearing less susceptible to the agents tested but with amphotericin B maintaining good activity.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15141336     DOI： 10.1007/s10096-004-1136-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  14 in total

Review 1.  In vitro antifungal susceptibility testing.

Authors:  H L Hoffman; M A Pfaller
Journal:  Pharmacotherapy       Date:  2001-08       Impact factor: 4.705

2.  Has antifungal susceptibility testing come of age?

Authors:  John H Rex; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2002-09-24       Impact factor: 9.079

3.  Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents.

Authors:  N Poonwan; Y Mikami; S Poosuwan; J Boon-Long; N Mekha; M Kusum; K Yazawa; R Tanaka; K Nishimura; K Konyama
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082

4.  In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.

Authors:  M A Pfaller; J Zhang; S A Messer; M E Brandt; R A Hajjeh; C J Jessup; M Tumberland; E K Mbidde; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  [Clinical aspects of AIDS at the Calmette hospital in Phnom Penh, Kingdom of Cambodia A report on 356 patients hospitalized in the Medicine "B" Department of the Calmette Hospital].

Authors:  K Pichith; H Chanroeun; P Bunna; N Nyvanny; S Thavary; S Kosal; P Crepin
Journal:  Sante       Date:  2001 Jan-Feb

6.  Comparison of broth macrodilution, broth microdilution and E-test susceptibility tests of Cryptococcus neoformans for fluconazole.

Authors:  E Chryssanthou; C Grönfors; N Khanna
Journal:  Mycoses       Date:  1997-12       Impact factor: 4.377

Review 7.  Review of the safety and efficacy of voriconazole.

Authors:  Holly L Hoffman; R Chris Rathbun
Journal:  Expert Opin Investig Drugs       Date:  2002-03       Impact factor: 6.206

Review 8.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

9.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

Authors:  M E Brandt; M A Pfaller; R A Hajjeh; R J Hamill; P G Pappas; A L Reingold; D Rimland; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 10.  In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.

Authors:  A Espinel-Ingroff; K Boyle; D J Sheehan
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785
View more
  12 in total

1.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008.

Authors:  Nelesh P Govender; Jaymati Patel; Marelize van Wyk; Tom M Chiller; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

2.  Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico.

Authors:  Gloria M González; Néstor Casillas-Vega; Elvira Garza-González; Romel Hernández-Bello; Gildardo Rivera; Jesús Ancer Rodríguez; Virgilio Bocanegra-Garcia
Journal:  Folia Microbiol (Praha)       Date:  2015-06-25       Impact factor: 2.099

3.  Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; G V Doern; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

4.  Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; A I Aller; E Canton; L R Castañón-Olivares; A Chowdhary; S Cordoba; M Cuenca-Estrella; A Fothergill; J Fuller; N Govender; F Hagen; M T Illnait-Zaragozi; E Johnson; S Kidd; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; G St-Germain; L Trilles; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

5.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; H Bijie; D Dzierzanowska; N N Klimko; V Letscher-Bru; M Lisalova; K Muehlethaler; C Rennison; M Zaidi
Journal:  J Clin Microbiol       Date:  2008-11-12       Impact factor: 5.948

6.  Chemosensitization as a means to augment commercial antifungal agents.

Authors:  Bruce C Campbell; Kathleen L Chan; Jong H Kim
Journal:  Front Microbiol       Date:  2012-02-29       Impact factor: 5.640

7.  Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities.

Authors:  C S Matos; A de Souza Andrade; N S Oliveira; T F Barros
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-01-26       Impact factor: 3.267

8.  Cryptococcus neoformans/gattii Species Complexes from Pre-HIV Pandemic Era Contain Unusually High Rate of Non-Wild-Type Isolates for Amphotericin B.

Authors:  Sujiraphong Pharkjaksu; Piriyaporn Chongtrakool; Methee Chayakulkeeree; Chalermchai Mitrpant; Pornpimon Angkasekwinai; John E Bennett; Kyung J Kwon-Chung; Popchai Ngamskulrungroj
Journal:  Infect Drug Resist       Date:  2020-02-26       Impact factor: 4.003

9.  Voriconazole in the management of nosocomial invasive fungal infections.

Authors:  Javier Pemán; Miguel Salavert; Emilia Cantón; Isidro Jarque; Eva Romá; Rafael Zaragoza; Angel Viudes; Miguel Gobernado
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

Review 10.  Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.

Authors:  Angela Loyse; Françoise Dromer; Jeremy Day; Olivier Lortholary; Thomas S Harrison
Journal:  J Antimicrob Chemother       Date:  2013-06-20       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.